High-density lipoprotein: why all the fuss?
The current search for new treatments to combat coronary heart disease (CHD) is centred on increasing HDL-cholesterol. The failure of the CETP inhibitor torcetrapib may force a rethink. This perspective briefly reviews the antiatherosclerotic properties of HDL and ways HDL-cholesterol concentration can be raised, but argues - in light of the fact that HDL-cholesterol concentration does not reflect the protective properties of HDL particles - that this approach is flawed and a different approach, targeting know antiatherosclerotic components of HDL, is required.
Mackness
Bharti
B
Pontech House, Cote Green Road, Marple Bridge, Stockport SK6 5EW, UK.
Mackness
Mike
M
D000924:Anticholesteremic Agents / Q000494:pharmacology; D003327:Coronary Disease / Q000378:metabolism / Q000517:prevention & control; D000960:Hypolipidemic Agents / Q000494:pharmacology; D008075:Lipoproteins, HDL / Q000378:metabolism* / Q000502:physiology*
D000924:Anticholesteremic Agents; D000960:Hypolipidemic Agents; D008075:Lipoproteins, HDL